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Abstract
Background: Despite considerable progress in the development of anticancer therapies, there is still a high
mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought
to be a source of tumor relapse and metastasis, and are therefore an obstacle to therapy. In this study, we
assessed the drug resistance of tumor cells in mice, and investigated whether vaccination could promote survival.
Methods: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to
drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the
efficacy of this vaccine.
Results: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line,
which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively,
treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional
therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro.
Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and
prolonged the overall survival of tumor-bearing mice.
Conclusions: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is
a possible treatment to complement traditional antitumor therapy.
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Background
In the majority of cancer cases, mortality is caused by
metastases, with only 10% being caused by the primary
tumor [1]. In many cancers, metastases and relapses
may occur several years or decades after disease remis-
sion. Disseminated tumor cells or residual treatment-
resistant tumor cells may persist in a so-called dormant
state until they are stimulated into an active cell-cycle
and initiate tumor recurrence [2]. Thus, these dormant
or ‘slow-cycling’ residual tumor cells are thought to be a
source of tumor relapse and metastasis, and are there-
fore an obstacle to therapy. However, the identification
and functional characterization of slow-cycling tumor
cells are still poorly understood.
It is accepted that slow-cycling tumor cells are more
drug-resistant than normal tumor cells, although direct
proof of this is lacking. The suggested mechanism of the
drug resistance of slow-cycling tumor cells is that their
minimal activity silences a vast spectrum of metabolic
loops targeted by anticancer drugs [3]. However, this the-
ory is still controversial, and more research is needed.
Clinical studies have recently shown that adding immu-
notherapy to chemotherapy has survival benefits com-
pared with chemotherapy alone, and can sensitize tumors
to immune-cell-mediated killing [4]. Cancer vaccination
with inactivated tumor cells is one form of immunother-
apy that is in common use. Studies that have identified
slow-cycling tumor cells as the source of tumor relapse
and metastasis have also indicated their possible use in
cancer vaccination. It is likely that some proteins with
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distinct immunogenicity are specifically expressed on the
surface of slow-cycling tumor cells, which therefore pro-
vides opportunities for enhanced immunotherapy.
In the present study, we investigated the tumorigenicity
and drug-resistant potential of slow-cycling tumor cells
compared with normal tumor cells, and found evidence
supporting the hypothesis that slow-cycling, drug-resistant
tumor cells are the source of tumor relapse and metastasis,
and are thus an obstacle to therapy. We found that, com-
pared with normal tumor cells, the inactivated slow-
cycling, drug-resistant cells induced greater proliferation
of spleen cells and higher production of interferon (IFN)-g
by these spleen cells in vitro. We also investigated the use
of such tumor cells in cancer vaccination. We found that
vaccination using the slow-cycling, drug-resistant tumor
cells induced a conspicuous immune response in mice
with colon carcinoma and remarkably prolonged the over-
all survival of the animals.
Methods
Ethics
Experimental research that is reported in the manuscript
have been performed with the approval of the Animal Care
and Welfare Committee of CIH-CAMS-PUMC (approval
date: 20 June 2009; approval number: 20120002). All the
experimental research on animals followed the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals (publication no. 85-23, revised 1985).
Mice
Female 6-week-old Balb/C mice (Animal Center of the
Chinese Academy of Medical Sciences, Beijing, China)
were kept under specific pathogen-free conditions.
Cell line and cell culture
All mouse tumor cell lines were cultured in RPMI 1640
medium (Gibco-BRL, Gaithersburg, MD, USA) supple-
mented with 10% FBS, at 37°C in a humidified atmo-
sphere containing 5% CO2. YAC-1: a mouse lymphoma
cell line which is a specific target for NK cells. We used
mouse TC-1 tumor cells derived from primary epithelial
cells of C57BL/6 mice co-transformed with HPV-16 E6,
E7 and c-Ha-ras oncogene (kind gift of Dr TC Wu, Johns
Hopkins Medical Institutions, Baltimore, MD, USA); 4T1
(a mammary gland tumor cell line from Balb/C mice
with high metastatic potency); and CT-26 (a colon tumor
cell line from Balb/C mice) (both American Type Culture
Collection (ATCC), Manassas, VA, USA).
DiI staining and cell sorting
Tumor cells were stained with DiI (Dil (1,1’-dioctadecyl
3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate); Invi-
trogen Corp., Carlsbad, CA, USA) in accordance with
the protocol for attached cells [5]. Cells were suspended
at a density of 1 × 106/ml in 1640 culture medium, DiI
solution was added at a concentration of 5 μl/ml and the
cell suspension was incubated at 37°C for 20 minutes.
After washing with phosphate-buffered solution (PBS)
with 2% FBS, the cells were analyzed and sorted using a
fluorescence-activated cell sorting (FACS) system (Vantage
SE; Becton Dickinson, Franklin Lakes, NJ, USA).
To determine the heterogeneity of tumor cells with
respect to cell-cycle length in vitro, DiI-labeled cells were
allowed to grow for 8 days in complete RPMI 1640 culture
medium under normal conditions, and were analyzed by
flow cytometry on days 1, 3, 5, and 8. To determine the
heterogeneity of tumor cells with respect to cell-cycle
length in vivo, DiI-labeled cells were injected subcuta-
neously into the left groin of Balb/C mice (2 × 106 cells
per mouse; four mice in total). Tumors were digested in
complete RPMI medium containing 1 mg/ml type IV col-
lagenase and 300 U/ml DNase I (Sigma AB, Göteborg.
Sweden) incubated for 30 min at 37°C, and analyzed by
flow cytometry on days 10, 15, and 25. When sorting, the
slow-cycling cells were identified as a bright positive
population.
Hoechst-Pyronin Y staining and cell sorting
Cells were detached from the cell-culture flask with 0.1%
trypsin, and Trypan blue-nonstaining viable cells were
counted and suspended at a density of 1 × 106/ml in
DMEM culture medium. Then they were stained with the
fluorescent dye Hoechst 33342 (Sigma AB) at a concentra-
tion of 5 μg/ml at 37°C for 45 minutes. At the end of this
time, 1 μg/ml of Pyronin Y (PY) was added, and cells were
incubated at 37°C for an additional 45 minutes as
described previously [6]. After washing with PBS plus 2%
FBS, the cells were analyzed and sorted (FACS Vantage
SE; Becton Dickinson). When sorting, cells residing in the
G0/G1 peak that simultaneously stained weakly with PY
were regarded as cells in G0 phase, and these were sorted
and used for further studies [7].
Side-population analysis
Cells were detached from the cell-culture flask with 0.1%
trypsin, and Trypan blue-nonstaining viable cells were
counted, and suspended at a density of 1 × 106/ml in
DMEM culture medium. Then they were stained with the
fluorescent dye Hoechst 33342 (Sigma AB) at a concentra-
tion of 5 μg/ml (37°C for 90 min) as described previously
[8]. After washing with PBS plus 2% FBS, the cells were
incubated with 2 μg/ml propidium iodide (PI) to exclude
dead cells, then cell analysis was performed (FACS Van-
tage SE; Becton Dickinson).
Tumor generation
Viable fast-cycling and slow-cycling tumor cells obtained
using the DiI-based FACS, and viable G0 and non-G0
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cells obtained by Hoechst-PY-based FACS, were stained
with Trypan blue and counted. Then cells of every
population were injected subcutaneously into the left
groin of Balb/C mice at a gradient dose of 5000, 1000,
or 500 cells. The mice were examined visually every day.
Chemotherapy resistant assay
To investigate the chemotherapy resistance of slow-cycling
cells in vivo, DiI-labeled cells (1 × 106 per mice) were
injected subcutaneously into Balb/C mice. When the
tumors had grown to 10 × 10 mm in size, 5-fluorouracil
(5-FU) 40 mg/kg was injected intraperitoneally every 3
days for a total of four injections. The vehicle control mice
were injected with PBS, using the same regimen. After the
final treatment, tumors were digested into a single-cell
suspension as described above, and analyzed by flow cyto-
metry the next day.
To determine the chemotherapy resistance of slow-
cycling cells in vitro, the same numbers of DiI-labeled
cells were seeded into a cell-culture flask (day 1), and
grown for 24 hours, then treated with 5-FU (day 2) at a
concentration of 1.5 μg/ml. On day 3, the medium was
replaced with fresh medium without 5-FU, and the cells
were grown under normal conditions for 24 hours. On
day 4, 5-FU 1.5 μg/ml was added into the medium
again, and cells were grown for a further 24 hours, then
on day 5, the medium was again replaced with fresh
medium without 5-FU, and cells were grown for another
24 hours. Finally, on day 6, cells were treated with tryp-
sin and analyzed by flow cytometry. The control cells
were treated in the same way but were never exposed to
5-FU.
To detect the inhibition of cell proliferation by 5-FU
in vitro, DiI-labeled cells of test group and control group
were seeded in triplicate into 96-well culture plate at 3,000
cells/well, then challenged with 5-FU 24 hours later in the
same manner above. On day 6, 3-(4,5-dimethylthiazol-
2-yl)- 2,5- diphenyltetrazolium bromide (MTT) method
was performed as described previously [9].
In vitro lymphocyte proliferation assay
Mixed lymphocyte tumor cell culture (MLTC) was used to
investigate the proliferation of spleen cells. Tumor-bearing
mice were killed by broken neck and spleens were har-
vested. The spleen tissue was ground and suspended in
PBS, then spleen cells were isolated using density gradient
centrifugation (Ficoll-Hypaque, Haoyang Biological Manu-
facture, Tianjin, China) and stored as a single-cell suspen-
sion. CT-26 cells treated with 5-FU (FU-CT-26) or not
(non-FU-CT-26) were exposed to mitomycin C (MMC)
for 1.5 hours, then these cells were seeded in triplicate at a
density of 1 × 104 cells per well in 96-well culture plates,
along with spleen cells (1 × 105 cells per well), and
incubated with interleukin (IL)-2 (100 U/ml) for 4 days at
37°C in a humidified 5% CO2 atmosphere. The MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay was used to test the lymphocyte proliferation
[9], and the results were expressed as:
proliferation index =
[
(A− B) /C]× 100%,
where A is the experimental absorbance from the spleen
plus tumor cell co-cultures, B is the absorbance from the
tumor cells alone, and C is the absorbance from the spleen
cells alone.
ELISA for the production of interferon-gamma (IFN-g)
CT-26 cells treated with 5-FU or not were exposed to
MMC for 1.5 hours, then these cells (2 × 105 cells per
well) were co-cultured separately with spleen cells (2 × 106
cells per well) from tumor-bearing mice at ratio of 1:10 in
400 μl complete RPMI 1640 containing IL-2 (100 U/ml)
for 3 days. The supernatant was collected on day 4, and
the concentration of IFN-g was analyzed using a mouse
IFN-g ELISA kit (eBioscience Inc., San Diego, CA, USA)
as described previously [10].
Flow cytometry and antibodies
The following anti-mouse monoclonal antibodies (mAbs)
were used for flow cytometry: anti-H2-Kd-PE (phycoery-
thrin conjugated); anti-major histocompatibility complex
(MHC) I-PE-Cy5; anti-CD80-FITC (fluorescein isothiocya-
nate) and anti-CD86-FITC (BioLegend, San Diego, CA,
USA). Flow cytometry was performed using a flow
cytometer (Epics XL; Beckman Coulter Inc., Brea, CA,
USA) equipped with Expo32 software (Beckman Coulter).
In vitro cytotoxic assay
Mice (three mice per group, and three groups in total)
were challenged with 3 × 105 CT-26 cells injected subcuta-
neously into the left groin (day 0), then separately immu-
nized with subcutaneous injection of FU or non-FU-CT-26
cells (1 × 106) that had also been pretreated with MMC on
days 3, 6, 9, 13, 18, and 25. 7 days after the final booster.
Spleen cells from the immunized mice (FU or non-FU-
CT-26 groups) were prepared as effector cells. Mice in the
control group were treated in the same way, but using PBS
for injection.
4T-1, YAC-1, and FU or non-FU CT-26 cells were used
as target cells. As described previously [11], target cells
were labeled with 5- (and 6-) carboxyfluorescein diace-
tate succinimidyl ester (CFSE; Sigma AB) for 10 minutes
at 37°C using a final concentration of 2 μmol/L. After label-
ing, the cells were washed once and re-suspended in com-
plete RPMI 1640. Effector and target cells were mixed to a
final volume of 200 μl in complete RPMI 1640, with the
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ratio of effector:target being 50:1. The tubes were mixed
and spun down at 120 × g for 2 minutes, then the samples
were incubated at 37°C for 4 hours. At the end of incuba-
tion time, 2.5 μg PI (Sigma AB) was added for DNA label-
ing of dead cells. The samples were then incubated
for 5 minutes and analyzed by flow cytometry within
60 minutes.
Vaccination treatment in a murine colon cancer model
To establish a colon cancer model, 3 × 105 CT-26 cells
were subcutaneously inoculated at the left groin of Balb/C
mice on day 0 (five mice per group, and five groups in
total). Then tumor cells were injected combined with or
not with granulocyte-macrophage colony-stimulating
factor (GM-CSF, 1 ng per mouse) on days 3, 6, 9, 13, 18,
25. The FU and non-FU CT-26 cells used in the earlier
vaccination were pretreated with MMC and injected sub-
cutaneously at 1 × 106 per mouse. Control mice were trea-
ted with PBS. Tumor growth was monitored every 2-3 days
by palpation, and tumor size was measured in two perpen-
dicular tumor diameters, as described previously [12].
Statistical analysis
Statistical significance of difference between the two
groups was determined by the Student paired t-test. The
Kaplan-Meier plot for survival was assessed for signifi-
cance using the log-rank test (SPSS software; version 12.0;
SPSS Inc., Chicago, IL, USA). P < 0.05 was considered
significant.
Results
Tumor cells exhibit clear heterogeneity in to cell-cycle
length both in vivo and in vitro
DiI is a long-term lipophilic tracer dye that can be
used to trace cell division and identify slow-cycling
cells. It has several advantages compared with PKH26,
such as a simpler protocol for cell labeling, lower
cytotoxicity, and higher resistance to intercellular
transfer [13]. This dye normally disappears at cell divi-
sion; however, slow-cycling cells may retain it for a
long time, which allows them to be identified by flow
cytometry. We found that DiI-retaining cells disap-
peared when they were allowed to grow in vitro or in
vivo (Figure 1A, B). A bright DiI-positive population
of cells (DiIhigh) was visible after 8 days in culture
(7.3% of cells; Figure 1A) or 25 days growing in vivo
(0.5% of cells; Figure 1B). Tumor cells exhibited clear
heterogeneity with respect to cell-cycle length both in
vivo and in vitro, with slow-cycling tumor cells (DiI-
high), cycling tumor (DiIlow) cells, and fast-cycling
tumor cells (DiI-negative cells) all being present.
Moreover, slow-cycling tumor cells only comprised a
small proportion of the tumor mass.
Slow-cycling tumor cells have the character of stem cells
Slow-cycling tumor cells are thought to be drug-resistant
and the source of relapse and metastasis. To investigate
the tumorigenic potential of this cell population, freshly
sorted slow-cycling and fast-cycling tumor cells were
injected subcutaneously into Balb/C mice, and their
tumor-formation ability was assessed.
A bright DiI-retaining population of cells was selected as
slow-cycling cells, and a population of DiI-negative cells
was selected as fast-cycling cells. After injection of 5,000
DiIhigh or DiI-negative cells, all five mice that received the
DiIhigh cells developed tumors, whereas only three of five
mice that received DiI-negative cells developed tumors.
Similarly, when the number of cells injected decreased to
1000, tumors formed in three of five mice that received
DiIhigh cells, whereas tumors were only seen in one of five
mice injected with the DiI-negative cells. After injection of
500 DiIhigh cells, only one of five mice had established
tumors, whereas no tumors were established from
DiI-negative cells (Table 1).
Analogous results were seen in cells sorted by Hoechst-
PY stain-based FACS. There are many dyes available for
determining G0/G1 versus S and G2/M phases based on
the DNA content measured by flow cytometry. However,
a DNA dye is not able to distinguish cells residing in G0
or G1 phases. This can be achieved by quantifying RNA
content (which increases during G1 and remains high dur-
ing mitosis) using PY in conjunction with the DNA dye
Hoeschst 33342 [14]. Tumor cells residing in the G0/G1
peak and simultaneously weakly stained by PY were sorted
as G0 cells (P2; Figure 2A), whereas tumor cells residing
in S phase were regarded as non-G0 cells (P3; Figure 2A).
The results of the tumor-generation assay were similar to
those of the assay mentioned in the previous paragraph.
Tumors formed in all five mice injected with 5,000 G0
cells, compared with two of five mice injected with 5,000
non-G0 cells (Table 2); in all five mice injected with 1,000
G0 cells, compared with only one of five mice injected
with 1,000 non-G0 cells; and in three of five mice injected
with 500 G0 cells, compared with none of the mice
injected with non-G0 cells. All these results indicated
increased tumorigenicity of slow-cycling tumor cells.
Until recently, side-population analysis has been one of
the accepted methods for identifying cancer stem cells
(CSCs) [15]. We investigated the percentage of side
populations in CT-26 cells (Figure 2B, right). We then
analyzed the number of G0 cells sorted by Hoechst-PY
staining-based FACS (Figure 2B, left) using side-popula-
tion analysis (Figure 2B, middle). G0 cells resided in
almost the same part of the coordinate axis (Figure 2B,
middle) as the side-population cells (Figure 2B, right),
and they had a similar proportion of tumor cells (2.6%
versus 2.4%; Figure 2B, middle and right). These findings
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Negative control Day 1 Day3 
Day5 Day8 
0.0%   0.8%   96.5% 0.0%   0.3%   94.3% 
4.6%   75.2%   16.4% 30.8%  58.4%  7.3% 




98.6%   0.8%   0.0% 0.0%   0.4%   94.4% 
91.2%  6.4%   0.4% 91.5%  6.8%   0.5% 
67.0%  24.8%  4.9% 
Day 25 Day 15 
Day 10 Negetive control Day 1 
Figure 1 The DiI-tracing assay showed that tumor cells exhibited clear heterogeneity with respect to cell-cycle length .
(A) DiI-labeled CT-26 cells were cultured in complete RPMI 1640 medium on day 1, and the percentage of DiI-retaining cells was analyzed
on days 1, 3, 5, and 8 by flow cytometry. (B) DiI-labeled CT-26 cells were injected subcutaneously into mice on day 1. On days 10, 15 and
25, tumors were excised and digested, and the percentage of DiI-retaining cells was analyzed by flow cytometry. Experiments were repeated
twice with similar results.
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and the increased tumorigenicity of slow-cycling tumor
cells indicated that they might have the character of
CSCs.
We found that although slow-cycling tumor cells
exhibited a higher tumorigenic potential, the average
number of days of tumor generation was prolonged com-
pared with that of fast-cycling cells (Table 1, Table 2).
Slow-cycling tumor cells are more resistant to
chemotherapy, both in vivo and in vitro
Slow-cycling tumor cells have always been predicted to
be resistant to traditional chemotherapy. We treated
CT-26 cells with 5-FU in vivo and in vitro to investigate
the sensitivity of slow-cycling cells and normal tumor
cells.
Table 1 Tumor-generation assay after using injection of 500, 1,000 or 5,000 DiI-positive cellsa, b.
Tumor generation, n/total n Mean time to tumor generation, days
cell injection 5,000c 1,000d 5,00d 5000 1000 500
DiIhigh cells 5/5 3/5 1/5 28 29 37
DiI- cells 3/5 1/5 0/5 21 24 –
aExperiments were repeated three times with similar results; this table presents the result of one experiment.
b DiIhigh cells were isolated using DiI-based fluorescence-activated cell sorting.









































Figure 2 Most cells in the G0 phase sorted by fluorescence-activated cell sorting (FACS) also resided in the same region as side-
population cells. (A) Hoechst-Pyronin Y (PY)-based FACS. The left and middle panels separately represent the Hoechst-staining control group
and PY-staining control group. In the Hoechst-PY-staining group (right), the P2 population represents the cells residing in G0 phase, and P3, cells
in S phase. (B) G0 cells sorted by Hoechst-PY-staining-based FACS (left panel) were measured by side-population analysis, and the result is
shown in the middle panel. The right panel represents the classic side-population analysis of CT-26 cells. The middle and right panels show that
most of the cells in G0 phase also resided in the region of the side-population cells. Experiments were repeated three times with similar results.
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Tumor volume in mice that received chemotherapy
decreased markedly compared with that in PBS-treated
mice (Figure 3B). However, after four treatments with
5-FU, the percentage of DiI-retaining slow-cycling cells
increased significantly, being 12% in tumors from mice
that received chemotherapy compared with 2.8% in
tumors from mice treated with PBS (Figure 3A, C).
Similarly, in vitro, 5-FU treatment obviously inhibited the
proliferation of tumor cells, as indicated by the absorbance
of MTT (Figure 4B). Tumor cells after chemotherapy were
analyzed by flow cytometry; most cells were DiI-retaining
slow-cycling cells (98.2%), while the percentage of DiL-
positive cells in the untreated group was only 2.8% (Figure
4A, C). These findings were consistent with the previous
prediction that slow-cycling tumor cells are an obstacle to
traditional chemotherapy.
5-fluorouracil-treated CT-26 cells induce increased
proliferation of and interferon-g production by spleen
cells in vitro
To investigate the potential of inducing proliferation of
and IFN-g production by spleen cells in vitro, FU and
non-FU CT-26 cells were treated with MMC and then
co-cultured with freshly isolated spleen cells in medium
containing IL-2. After 3 or 4 days culture, an MTT
assay was performed to analyze the proliferation rate.
To investigate the efficacy of MMC, the proliferation of
MMC-treated FU-CT-26 and non-FU-CT-26 cells was
analyzed. No proliferation was seen in either group of
tumor cells after treatment with MMC, which indicates
that MMC could be used to inactivate both FU and
non-FU CT-26 cells (Figure 5B). The FU-CT-26 cells
had a higher proliferation index than the non-FU-CT-26
cells (2.11 versus. 1.70; Figure 5B).
Culture supernatant was collected and used for IFN-g
analysis by ELISA. FU-CT-26 cells induced more IFN-g
production in spleen cells compared with CT-26 cells
(Figure 5C). The concentrations of IFN-g in the superna-
tant of the FU-CT-26 plus spleen cell mixture was 1602 ±
55, that of the non-FU-CT-26 plus spleen cells was 750 ±
24, and that of the spleen cells alone was 54 ± 11 pg/ml,
respectively.
In conclusion, compared with non-FU-CT-26 cells, FU-
CT-26 cells induced a more intense immune response.
Immunotherapy with inactivated fluorouracil-treated CT-
26 cells plus granulocyte-macrophage colony-stimulating
factor produces a therapeutic effect in a CT-26 colon
cancer mouse model
The preceding results provided strong information that
slow-cycling tumor cells may be a better immunogen
that could induce an intense antitumor response. To
investigate whether immunization with inactivated FU-
CT-26 cells could obtain a better therapeutic effect in
vivo, we established a subcutaneous CT-26 mouse
model and immunized them separately with inactivated
CT-26 and FU-CT-26 combined with GM-CSF. Tumors
in mice treated with FU-CT-26 or non-FU-CT-26 cells
plus GM-CSF, or non-FU-CT-26 cells alone were all
clearly reduced compared with those in mice treated
with PBS (control group). Immunization with the FU-
CT-26 cells plus GM-CSF produced the best therapeutic
effect (Figure 6A). Treatment with FU-CT-26 cells plus
GM-CSF prolonged survival of tumor-bearing mice (Fig-
ure 6B). Both the mice treated with PBS and the mice
treated with the non-FU-CT-26 cells all died, with a
median survival of 32.8 and 40.2 days, respectively. The
mice immunized with FU-CT-26 and non-FU-CT-26
cells plus GM-CSF had comparable results, with median
survival of 50.7 and 48.5 days, respectively. When survi-
val was monitored for up to 80 days after inoculation,
one mouse in each group was still alive. However, treat-
ment with FU- CT-26 cells plus GM-CSF exhibited the
best outcome, with a median survival of 61.5 days, and a
60% survival rate (three of five mice) when survival was
monitored up to 80 days after inoculation.
We rechallenged the mice that survived after immu-
notherapy (one treated with FU-CT-26 cells alone, one
with non-FU-CT-26 cells plus GM-CSF, and three with
FU-CT-26 cells plus GM-CSF) with 106 non-FU-CT-26
cells. None of these five surviving mice had established
tumors, which indicated that immunotherapy with inacti-
vated FU-CT-26 and non-FU-CT-26 cells induced a speci-
fic memory immune response in vivo.
Table 2 Tumor-generation assay using injection of 500, 1,000 or 5,000 G0 cellsa, b.
Tumor generation, n/total n Mean time to tumor generation, days
cell injection 5,000c 1,000c 500c 5,000 1,000 500
G0 5/5 5/5 3/5 25.4 26.6 27.6
Non-G0 2/5 1/5 0/5 22 21 –
a, b
aExperiments were repeated three times with similar results; this table presents the result of one experiment.
bG0 cells were isolated using Hoechst-Pyronin Y-based fluorescence-activated cell sorting.
cThe t-test was carried out to determine the difference between the two groups in three experiments: cP < 0.01.
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Immunocytes activated by 5-fluorouracil (FU) CT-26 cells
show specific and intense cytotoxicity to FU-CT-26 and
non-FU-CT-26 cells
Immunization with inactivated FU-CT-26 cells showed a
clear therapeutic effect in vivo, therefore, we investigated
the mechanism involved. First, we investigated the sensi-
tivity of slow-cycling tumor cells to killing by cytotoxic
T lymphocytes (CTLs). Spleen cells from tumor-bearing
mice were isolated, and their cytotoxicity against FU-
CT-26 and non-FU-CT-26 cells was analyzed in vitro.
A 




DiI+ 0.5% DiI- DiI+ 2.8% DiI- DiI+ 12% DiI- 
5-Fu treated PBS treated Negative 
***
*
Figure 3 Chemotherapy-induced enrichment of DiI-retaining cells in vivo. (A) DiI-retaining tumor cells were enriched in vivo after treatment
with 5-fluorouracil (FU). Negative: flow cytometry of CT-26 cells that were not stained with DiI: PBS-treated: flow cytometry of cells from tumor
treated with phosphate-buffered saline (PBS); 5-FU-treated: flow cytometry of cells from tumor treated with 5-FU. (B) Tumor volume in mice after
chemotherapy compared with the PBS-treated group (*P < 0.05, t-test). (C) Percentage of DiI-positive cells in tumors with or without
chemotherapy (**P < 0.01, t-test). Error bars represent the standard deviation. DiI-labeled CT-26 cells were injected subcutaneously into Balb/C
mice on day 1. When tumors grew to 10 × 10 mm, 5-FU 40 mg/kg was injected intraperitoneally every 3 days for a total of four injections.
Vehicle-treated control mice were exposed to the same regimen, but injected only with PBS. Tumor volume was measured on days 7, 14, and
21. After the final treatment, tumors were digested and analyzed by flow cytometry on the next day. Experiments were repeated twice with
similar results.
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CTLs showed 11.85% cytotoxicity against FU-CT-26 cells
compared with 21.67% cytotoxicity against non-FU-CT-
26 cells (Figure 7A). These data indicate that slow-
cycling, drug-resistant tumor cells were also resistant
to cytotoxic killing, and this coincided with the clinical
data.
Second, we investigated whether immunocytes acti-
vated by FU-CT-26 cells exhibited specific and obvious
cytotoxicity against normal and slow-cycling tumor cells.
The cytotoxicity of the induced spleen cells immunized
with inactivated non-FU-CT-26 and FU-CT-26 cells was
evaluated against a series of cells by flow cytometry.
A 
 
B                                 C 




Negative control Untreated  5-Fu treated 
99.7%  0.1%  0.0% 
** ** 
Figure 4 Chemotherapy-induced enrichment of DiI-retaining cells in vitro. (A) DiI-retaining tumor cells were enriched in vitro after
treatment with 5-fluorouracil (FU). DiI-labeled CT-26 cells were cultured in complete RPMI 1640 medium and exposed to 5-FU on day 2. The old
medium was changed for fresh medium without 5-FU on day 3, then 5-FU was added again on day 4. Cells were harvested on day 6 and
analyzed by flow cytometry. The control group was cultured without 5-FU. (B) Persistence of cells after 5-FU treatment. The same numbers of
CT-26 cells were seeded into 96-microwell plates. The 5-FU-treated group was treated as described above, and the untreated group was
cultured without 5-FU. An MTT assay was performed 5 days later. (**P < 0.01, t-test) (C) Percentage of DiI-positive cells in vitro after 5-FU
treatment. (**P < 0.01, t-test). Experiments were repeated twice times with similar results. Error bars represent the SD.
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Figure 5 5-fluorouracil (FU)-treated CT-26 cells induced increased proliferation and interferon (IFN)-g production by spleen cells.
(A) Proliferation curve of FU-treated and non-FU-treated CT-26 cells after treatment with mitomycin C (MMC). No proliferation was seen with
either of the tumor cells, which confirmed the efficacy of MMC. (B) Spleen cells from tumor-bearing mice had significantly higher proliferation
after co-culture with FU-CT-26 cells compared with non-FU-CT-26 cells, at a responder:stimulator (R:S) ratio of 10:1. (*P < 0.05, t-test) (C) IFN-g
production by spleen cells after co-culture with 5FU-treated CT-26 cells compared with CT-26 cells. (*P < 0.05, t-test). Error bars represent the
standard deviation. CON: control spleen cells cultured without tumor cells. Mixed lymphocyte tumor cell culture (MLTC) was performed to
investigate the proliferation of and IFN-g production by spleen cells. Spleen cells were harvested from tumor-bearing Balb/C mice. The same
numbers of FU-CT-26 and non-FU-CT-26 cells were seeded into 96-microwell plates. Spleen cells were added at an R:S ratio of 10:1 on day 1,
and proliferation of spleen cells was analyzed by MTT assay on day 4. As for IFN-g production, the same numbers of FU-CT-26 and non-FU-CT-26
cells were seeded into 24-well plates. Spleen cells were added at an R:S ratio of 10:1. The supernatant was collected on day 4, and IFN-g
concentration was analyzed by ELISA.
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Figure 6 Therapeutic efficacy of inactivated 5-fluoracil-treated CT-26 cells plus granulocyte-macrophage colony stimulating factor
(GM-CSF) against subcutaneous CT-26 tumor in Balb/C mice. (A) Tumor volume of mice in the FU-CT-26 + GM-CSF group decreased
significantly compared with other groups. (P < 0.05, ANOVA) Error bars represent the standard deviation. (B) Kaplan-Meier survival analysis shows
that mice treated with inactivated FU-CT-26 cells combined with GM-CSF had longer survival than other groups (P < 0.01). CT-26 cells (106) were
injected subcutaneously into Balb/C mice on day 0. Tumor-bearing mice were vaccinated subcutaneously on days 3, 6, 9, 13, 18, and 25 with
different cell vaccines. FU-CT-26+GM: mice immunized with mitomycin C (MMC)-inactivated FU-CT-26 cells (106) plus GM-CSF. FU-CT-26: mice
immunized with MMC-inactivated FU-treated CT-26 cells (106). CT-26+GM: mice immunized with MMC-inactivated CT-26 cells (106) plus GM-CSF.
CT-26: mice immunized with MMC-inactivated CT-26 cells (106). Control: mice treated with phosphate-buffered saline. Experiments were repeated
three times with similar results.
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Figure 7 Cytotoxicity analysis using carboxyfluorescein diacetate succinimidyl estercarboxyfluorescein diacetate succinimidyl ester
(CFSE)-propidium iodide (PI) staining-based Flow cytometry. CFSE- and PI-positive target cells represent cells lysed by effector cells.
(A) Spleen cells from tumor-bearing mice killed fewer slow-cycling and drug-resistant 5-fluorouracil (FU)-treated CT-26 tumor cells. No significant
differences were seen (t-test). (B) Spleen cells from tumor-bearing mice immunized with inactivated FU-CT-26 or non-FU-CT-26 cells showed
tumor-specific cytotoxicity in vitro, and spleen cells from mice immunized with inactivated FU-CT-26 cells exhibited higher cytotoxicity compared
with the other two groups. (*P < 0.05, **P < 0.01, t-test) Error bars represent the standard deviation. From left to right, the target cells
respectively were FU-CT-26, non-FU-CT-26, 4T-1, and YAC-1 cells. Effector:target cell ratio was 50:1. SP/FU-CT-26: Spleen cells from tumor-bearing
mice immunized with mitomycin C (MMC)-inactivated FU-CT-26 cells. SP/non-FU-CT-26: Spleen cells from tumor-bearing mice immunized with
MMC-inactivated CT-26 cells. SP/Control: Spleen cells from tumor-bearing mice treated with PBS. Experiments were repeated three times with
similar results.
Sun et al. BMC Medicine 2012, 10:172
http://www.biomedcentral.com/1741-7015/10/172
Page 12 of 15
Immunization with FU or non-FU CT-26 cells induced
tumor-specific cytotoxicity; the cytotoxicity against 4T-1
and YAC-1 cells was less than 10%, whereas the cytotoxi-
city against FU and non-FU CT-26 cells was much higher
(Figure 7B). Moreover, compared with spleen cells from
mice immunized with non-FU-CT-26 cells (SP/non-FU-
CT-26), spleen cells from mice immunized with FU-CT-26
cells (SP/FU-CT-26) exhibited higher cytotoxic potential
against non-FU-CT-26 cells (SP/FU-CT-26:57 ± 5% versus
SP/non-FU-CT-26: 30 ± 3%) and FU-CT-26 cells (SP/FU-
CT-26: 35 ± 10% versus SP/non-FU-CT-26:17 ± 1%).
Upregulation of major histocompatibility complex and co-
stimulatory molecules on the surface of fluorouracil-
treated CT-26 cells
Using flow cytometry, we analyzed the expression of
MHC class I and II molecules and co-stimulatory mole-
cules on the surface of FU and non-FU CT-26 cells.
Although the expression of MHC class I molecules was
comparable in both FU and non-FU cells (92.7 ± 2.76%
versus 99.1 ± 1.27%), the average fluorescence intensity
of MHC class I expressed by the FU-CT-26 cells was
much lower (13.6 ± 0.21 versus 38.9 ± 2.34). However,
compared with the non-FU-CT-26 cells, the expression
level and average fluorescence intensity of MHC class II
molecules and of the co-stimulatory molecules CD80
and CD86 on the surface of FU-CT-26 cells were all
clearly upregulated (Table 3), although the expression
level of MHC class II molecules and CD86 was not high.
To confirm this finding, we analyzed the expression of
the molecules on the surface of 5-FU-treated 4T-1 and
TC-1 or untreated 4T-1 and TC-1 tumor cells by flow
cytometry, and a similar tendency was seen (Table 3).
These findings indicate that increased expression of
MHC class II molecules and the co-stimulatory mole-
cules CD80 and CD86 may be the reason why drug-
treated tumor cells can induce a more significant
immune response, and lower expression of MHC class I
molecules could be one reason for the resistance of
slow-cycling tumor cells to cytotoxic killing.
Discussion
Tumor dormancy has been recognized for many years as
a clinical phenomenon in several types of cancer. Clini-
cians and experimental biologists have used the term
‘dormancy’ to describe the hypothetical state of cancer
cells lying in wait for some time after treatment of the
primary tumor, before the tumor’s subsequent growth
and clinical recurrence [2,16]. Tumors in dormancy are
mainly constructed of quiescent or slow-cycling tumor
cells. Quiescent tumor cells can be detected in the mar-
row of many patients in the tumor-remission phase, and
these patients often develop tumor relapse or metastasis
[17-19]. However, there is insufficient evidence to prove
that these cells are the origin of tumor relapse. Thus,
more research into the identification and biologic char-
acter of quiescent or slow-cycling tumor cells is needed.
In the present study, we used a membrane-bound dye,
DiI, to identify slow-cycling cancer cells in vitro and in
vivo. Our data directly confirm the existence of quiescent
cells in growing colon tumor, and this cell population
comprised only a small proportion of the tumor mass.
Compared with other label-retention methods, DiI is
simpler to use and yields easy identification of quiescent,
label-retaining cells. However, it is important to note that
the best time for analysis will differ depending on the
type of tumor, because of the distinct proliferation cycle
of different cells.
Many human cancers contain CSCs that are responsible
for initiating and maintaining tumor growth and resistance
to therapy [20-23]. The quiescent state seems to be neces-
sary for preserving self-renewal of stem cells [24], and is a
Table 3 Expression levels and fluorescence intensity of MHC and co-stimulatory molecules on the surface of 5-FU-
treated cellsa, b.
Cell type Percentage of molecule expression, % Average fluorescence intensity
MHC I MHC II CD80 CD86 MHC I MHC II CD80 CD86
CT-26
Treated 92.7 ± 2.76 10.0 ± 1.56c 92.4 ± 7.85 9.2 ± 1.84c 13.6 ± 0.21c 12.5 ± 0.42d 4.3 ± 0.14c 3.5 ± 0.49c
Untreated 99.1 ± 1.27 1.5 ± 0.14 83.4 ± 6.58 3.1 ± 2.47 38.9 ± 2.34 5.0 ± 0.49 2.7 ± 0.35 1.8 ± 0.64
TC-1
Treated 92.4 ± 2.69 1.6 ± 0.49 95.9 ± 4.03 5.3 ± 0.10c 3.0 ± 0.35c 3.6 ± 0.92c 10.7 ± 0.99c 2.9 ± 1.06
Untreated 97.5 ± 2.47 0.4 ± 0.07 95.0 ± 1.27 1.6 ± 0.49 8.2 ± 0.78 2.3 ± 0.64 5.6 ± 0.14 1.8 ± 0.71
4T-1
Treated 69.7 ± 6.65 10.5 ± 1.13d 11.3 ± 1.27c 7.8 ± 1.27c 2.6 ± 0.49c 5.4 ± 0.49c 4.4 ± 0.85 3.5 ± 1.06
Untreated 84.4 ± 0.64 2.4 ± 1.20 2.7 ± 0.71 1.8 ± 0.07 3.8 ± 0.07 3.2 ± 0.64 2.7 ± 1.13 2.4 ± 0.92
Abbreviations: MHC, major histocompatibility complex.
aExperiments were repeated twice with similar results.
bData are expressed as mean ± SD of the two independent experiments.
c, dThe t-test was carried out to determine the difference between the two groups in three experiments: cP < 0.05, dP < 0.01, t-test).
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crucial factor in resistance to chemotherapy and targeted
therapies [25-27]. In the present study, we used a tumor-
forming assay to show the self-renewing potential of slow-
cycling tumor cells in vivo. Simultaneous side-population
analysis of the cell line indicated that CSCs were enriched
in the slow-cycling population. It was particularly interest-
ing that, although more transplanted tumors were seen in
mice injected with slow-cycling tumor cells, the average
tumor-forming time was longer than with the fast-cycling
cells (Table 1, Table 2). This may because slow-cycling
tumor cells take a long time to exit the quiescent state,
and then expand and differentiate in response to stress.
This finding indicates that, if the mechanism that causes
recycling of quiescent cells could be elucidated and the
crucial point of the pathway inhibited, this recycling could
be inhibited, preventing tumor relapse and metastasis.
Moreover, we found that, although the number of tumor
cells and the volume of the tumor were reduced by drug
treatment, the remnant was composed of drug-resistant,
slow-cycling cells. These results provide evidence that
slow-cycling tumor cells are resistant to traditional che-
motherapy and are responsible for initiating tumor relapse
and metastasis.
Conventional chemotherapy optimally targets highly pro-
liferative tumor cells, and the existence of drug-resistant,
slow-cycling tumor cells limits improvements in recur-
rence-free and overall survival rates. In this study, we
found that drug-resistant tumor cells are mostly slow-
cycling, and this population increased the proliferation of
and IFN-g production by spleen cells in vitro. Moreover,
our in vivo experiments showed that, compared with nor-
mal tumor cells, vaccination with slow-cycling tumor cells
generated a more effective immune response and pro-
longed the overall survival of tumor-bearing mice.
Although the slow-cycling population was more resis-
tant to CTL cytotoxicity than the conventional tumor
cells, this population could induce a more intense
immune response, as shown by the enhanced cytotoxicity
of spleen cells from mice immunized with slow-cycling
tumor cells. More importantly, we found that these slow-
cycling cells expressed a lower level of MHC class I mole-
cules, but a higher level of class II, as well as a higher
level of the co-stimulatory molecules CD80 and CD86,
compared with conventional tumor cells. We speculate
that the low expression of MHC class I molecules may
have caused the resistance to killing by CTLs, whereas
the upregulation of MHC class II and co-stimulatory
molecules may be one reason for the increased induction
of the immune response.
However, more questions remain about the mechan-
isms underlying the apparently superior outcomes from
vaccination with slow-cycling tumor cells. For example,
is there any difference between slow-cycling tumor cell
antigens and conventional tumor lysates in inducing
effector cell differentiation and memory T-cell genera-
tion? Further studies into different aspects of these
tumor cells are needed. For instance, differences in gene
expression between slow-cycling and conventional
tumor cells have been analyzed by gene chip technology,
and we have now found a series of overexpressed genes
in slow dividing cells. One of these antigens, which has
been reported to be a testicular cancer antigen, has par-
ticularly attracted our attention. However, further
research into this gene and its related protein is needed.
The results of the present study all indicate that slow-
cycling tumor cells are a better source of antigens for
cancer immunization than conventional tumor cells. To
date, the primary treatment for eliminating slow-cycling
tumor cells is to induce them to enter the cell cycle and
then kill them using traditional methods [2,28]. However,
immunotherapy, as performed in our study, could selec-
tively target the only slow-cycling tumor cells, resulting
in elimination of the source of tumor recurrence and
metastasis. Compared with conventional treatment, this
technique could effectively reduce the risk of tumor
recurrence and metastasis. Although several studies have
shown that vaccination using stem-cell antigens induces
a more effective immune response against prostate,
brain, and ovarian cancers [29-31], there is controversy
regarding the identification and isolation of CSCs in dif-
ferent tumors. Our results indicate that slow-cycling
tumor cells could enrich CSCs, and the process we used
to harvest slow-cycling tumor cells is easier to perform.
Thus, the clinical application of this immunotherapy
shows good prospects.
Conclusions
In this study, we showed that slow-cycling tumor cells
induced an antitumor immune response, especially of
tumor-specific CTLs, with enhanced killing of drug-resis-
tant tumor cells, and vaccination with slow-cycling tumor
cells could prolong the overall survival of tumor-bearing
mice. Our data also indicated that this treatment not only
kills normal tumor cells, but also selectively targets the
slow-cycling tumor cells, thus reducing the risk of cancer
metastasis and relapse. Moreover, this vaccine has excel-
lent histocompatibility, because slow-cycling tumor cells
are isolated from the tissues of the recipient; thus, no
severe side-effects should occur. To our knowledge, this is
the first study of its kind. All our findings suggest that
immunotherapy with inactivated slow-cycling tumor cells
is a possible strategy to complement traditional cancer
treatment.
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